Windlas Biotech Limited (WINDLAS) Q2 FY27 Financial Results: PAT ₹25 & Revenue ₹248 Cr
| Metric | Value |
|---|---|
| Revenue | ₹248 Cr |
| Net Profit (PAT) | ₹25 |
Windlas Biotech Limited reported record Q1 FY27 revenue of ₹248 crores, up 18% YoY, driven by strong CDMO growth, while adjusted EBITDA rose 26% to ₹34 crores and adjusted PAT increased 37% to ₹25 crores. The company completed a ₹47 crore share buyback without promoter participation and declared a ₹13 crore dividend (₹6.30 per share) for FY26. CDMO vertical contributed 84% of consolidated revenue, with exports growing 79% YoY to ₹11 crores. Management highlighted strategic focus on capacity expansion, portfolio development, and long-term shareholder value creation amid a stable pharmaceutical market.
About Windlas Biotech Limited (WINDLAS)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when WINDLAS files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track WINDLAS — Free💡 Ask AI about this filing
📊 More WINDLAS filings
- Announcement — 11 August 2026 Windlas Biotech announced that the audio recording of its investor conference call discussing unaudi...
- 🔴 Financial Results — 24 July 2026 No summary available
- 🟡 Board Meeting — 23 July 2026 Windlas Biotech held its 25th Annual General Meeting on July 23, 2026 via video conference, with 63 ...
- 🔴 Annual Report — 2 July 2026 Windlas Biotech announced completion of its 25th AGM and Annual Report for FY2025-26 via newspaper a...
- 🟡 Board Meeting — 1 July 2026 Windlas Biotech announced its 25th AGM on July 23, 2026, via video conference, where shareholders wi...
🔥 Also filed on 10 August 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when WINDLAS files new disclosures
Track WINDLAS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track WINDLAS — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research